Skip to main content

Table 3 Incidence rates, hazard ratios, and confidence intervals of HCC among different stratifications of HCV patients with and without aspirin use

From: Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study

Variables

Aspirin

Aspirin VS. Non-aspirin

No

(n = 1911)

Yes

(n = 1911)

Crude HR

(95% CI)

Adjusted HR

(95% CI)

Event

Person years

IR†

Event

Person years

IR†

Overall

147

6848

2.15

131

8546

1.53

0.73(0.58–0.93)**

0.56(0.43–0.72)***

Gender

 Female

66

3838

1.72

57

4707

1.21

0.72(0.51–1.03)

0.51(0.35–0.76)***

 Male

81

3010

2.69

74

3839

1.93

0.72(0.53–0.99)*

0.59(0.42–0.83)**

Age, years

  < 40

0

592

0

2

633

0.32

  

 40–59

31

2929

1.06

27

3069

0.88

0.83(0.5–1.39)

0.64(0.35–1.14)

 60–79

98

2888

3.39

94

4325

2.17

0.65(0.49–0.87)**

0.56(0.41–0.76)***

  ≥ 80

18

440

4.09

8

518

1.54

0.44(0.19–1.01)

0.45(0.18–1.11)

Baseline comorbidity

 Hypertension

  No

39

1713

2.28

31

2557

1.21

0.55(0.34–0.88)*

0.39(0.23–0.65)***

  Yes

108

5135

2.1

100

5989

1.67

0.81(0.62–1.06)

0.63(0.47–0.85)**

 Diabetes mellitus

  No

90

3692

2.44

79

5060

1.56

0.65(0.48–0.88)**

0.49(0.35–0.68)***

  Yes

57

3156

1.81

52

3486

1.49

0.85(0.58–1.24)

0.68(0.45–1.03)

 Moderate or severe liver disease

  No

145

6711

2.16

130

8468

1.54

0.73(0.57–0.92)**

0.56(0.43–0.73)***

  Yes

2

137

1.46

1

78

1.28

0.8(0.07–8.85)

 

 Myocardial infarction

  No

143

6443

2.22

126

8057

1.56

0.72(0.57–0.92)**

0.55(0.42–0.72)***

  Yes

4

405

0.99

5

489

1.02

1.02(0.27–3.82)

0.72(0.16–3.23)

 Congestive heart failure

  No

127

5443

2.33

103

6969

1.48

0.65(0.5–0.84)**

0.52(0.39–0.69)***

  Yes

20

1406

1.42

28

1577

1.78

1.25(0.7–2.23)

0.79(0.42–1.5)

 Ischemic stroke

  No

66

2754

2.4

60

3858

1.56

0.66(0.46–0.93)*

0.48(0.33–0.71)***

  Yes

81

4094

1.98

71

4688

1.51

0.79(0.58–1.09)

0.62(0.43–0.88)**

Drugs

 Anti-hypertensive agents

  No

56

4333

1.29

19

2189

0.87

0.69(0.41–1.16)

0.58(0.33–1.01)

  Yes

91

2515

3.62

112

6357

1.76

0.51(0.38–0.67)***

0.53(0.4–0.71)***

 Hypoglycemic agents

  No

141

6548

2.15

124

8056

1.54

0.73(0.57–0.93)*

0.55(0.42–0.72)***

  Yes

6

300

2

7

490

1.43

0.65(0.21–2.03)

0.71(0.2–2.52)

 Coumadin and heparin

  No

145

6765

2.14

126

8037

1.57

0.75(0.59–0.95)*

0.56(0.43–0.73)***

  Yes

2

83

2.4

5

509

0.98

0.4(0.07–2.19)

0.41(0.05–3.18)

 Other antithrombotic agents

  No

136

6531

2.08

96

6703

1.43

0.71(0.54–0.92)**

0.53(0.4–0.7)***

  Yes

11

318

3.46

35

1843

1.9

0.56(0.29–1.12)

0.68(0.34–1.37)

 NSAIDs

  No

69

3535

1.95

65

3108

2.09

1.07(0.76–1.5)

0.79(0.54–1.14)

  Yes

78

3313

2.35

66

5437

1.21

0.54(0.39–0.74)***

0.41(0.29–0.59)***

  1. Abbreviations: IR† Incidence rates, per 100 person-years, HR Hazard ratio, CI Confidence interval, NSAIDs Non-steroidal anti-inflammatory drugs
  2. * p < 0.05, ** p < 0.01, *** p < 0.001
  3. Adjusted HR: adjusted for gender, age, hypertension, diabetes mellitus, moderate or severe liver disease, myocardial infarction, congestive heart failure, ischemic stroke, anti-hypertension agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents and NSAIDs in Cox proportional hazards regression
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us